Photocure is a Norwegian pharmaceutical company focusing on the use of photodynamic technology to detect and cure diseases. Photocure was founded in 1993 by the Norwegian Radium Hospital with the first employee being hired in 1997. Today, the company has 57 highly competent employees, including seven employees holding Ph.D.s, and operates in Norway, Sweden, Denmark and Finland.
Photocure’s strategy is to develop new and innovative products to fulfill unmet medical needs based on its patented photodynamic technology.
Photocure’s marketing strategy is to market and sell in the Nordic region and to sign licensing agreements for marketing and distribution outside this region. In January 2006, Photocure licensed Hexvix to GE Healthcare, a global leader in imaging.
Photocure has one product with sales and marketing approvals:
- Hexvix, for the detection of bladder cancer.
Photocure relies on outsourcing when it comes to production and R&D, but it is tightly controlled by internal project management.
Photocure is currently evaluating its patented photodynamic technology for several diseases such as acne, pre-malignant cervix lesions/HPV-infections, colon cancer and for improving the appearance of the skin.